Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bromocriptine mesilate
- Development stage
- Approved
- Lead developer
- Kyoto University
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Bromocriptine mesilate is a repurposed small molecule drug originally known as a dopamine D2 receptor agonist used for Parkinson's disease, hyperprolactinemia, acromegaly, and type 2 diabetes. It is being investigated for the treatment of familial Alzheimer's disease carrying presenilin 1 (PSEN1) mutations (PSEN1-AD). Identified through induced pluripotent stem cell (iPSC)-based drug repurposing, bromocriptine mesilate has been shown to reduce the production of amyloid-beta. The drug is developed by Kyoto University, Time Therapeutics, and Towa Pharmaceutical, and is administered orally.
- Brand names
- AberginBarlolinBramestonBrocriptinBromBroma-DelBromergocryptineBromergonBromiconBromocornBromodelBromokriptinBromolacBromotineBromtineBrotinButinCorpadelCripsaCriptineCritenCyclosetDegalaDemilDeparoDeprolacDiacriptinDopagonErenantGrifocriptinaGynodelKirimKriptonalLactodelMedocriptineMelenPadoparinePalolactinParlodelPravidelProctinalPseudogravinRonalinSemi-BromSerocriptinSerocryptinSuplacSyntocriptineUmprelUnewUpdopaUpnol BVolbro
- Other names
- 2-bromo-alpha-ergocryptine2-bromoergocriptinebromocriptinebromocriptine mesilatebromocriptine mesylatebromocriptine methanesulfonatebromocriptini mesilasbromocriptinmesilatbromocriptinumergolactin
02
Targets
HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))Aβ (Amyloid-beta peptides and aggregates)DRD2 (Dopamine D2 Receptor)DRD3 (Dopamine receptor D3)
Beyond the preview
Go deeper on bromocriptine mesilate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bromocriptine mesilate.